Comparative Pharmacology
Head-to-head clinical analysis: EFFEXOR versus EFFEXOR XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFFEXOR versus EFFEXOR XR.
EFFEXOR vs EFFEXOR XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits serotonin and norepinephrine reuptake by blocking the serotonin transporter (SERT) and norepinephrine transporter (NET), increasing extracellular concentrations of serotonin and norepinephrine in the CNS.
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It potently inhibits the reuptake of serotonin and norepinephrine, and weakly inhibits dopamine reuptake. It has no significant affinity for muscarinic, histaminergic, or alpha1-adrenergic receptors.
Initial: 75 mg/day PO in 2-3 divided doses; may increase by 75 mg/day increments at intervals of 4 days or more; max 375 mg/day. Extended-release: initial 37.5-75 mg PO once daily, titrate up to max 225 mg/day.
75 mg orally once daily; may increase by 75 mg/day increments every 4-7 days to max 225 mg/day.
None Documented
None Documented
Venlafaxine: ~5 ± 2 hours; ODV (active metabolite): ~11 ± 2 hours. At steady state, effective half-life for total active moiety (venlafaxine + ODV) is ~11 hours. Clinical context: requires twice-daily dosing for immediate-release; extended-release formulations allow once-daily dosing.
Venlafaxine: 3-7 hours (short, requires extended-release formulation for once-daily dosing); active metabolite O-desmethylvenlafaxine: 9-13 hours (contributes to overall clinical effect). Steady-state achieved within 3 days.
Primarily renal (≈87% of dose eliminated in urine), with approximately 29% as unchanged venlafaxine, 26% as unconjugated O-desmethylvenlafaxine (ODV), and the remainder as other metabolites. Fecal elimination accounts for <10%. Biliary excretion is negligible.
Renal: approximately 87% as metabolites (including venlafaxine, O-desmethylvenlafaxine, and other minor metabolites) and ≤5% as unchanged drug. Biliary/fecal: minimal (about 2%).
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant